Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (52) 52
index medicus (50) 50
male (49) 49
humans (48) 48
female (29) 29
azocines - therapeutic use (26) 26
varenicline (24) 24
smoking cessation - methods (23) 23
azocines - pharmacology (22) 22
rats (22) 22
alkaloids - therapeutic use (21) 21
alkaloids - pharmacology (20) 20
quinolizines - therapeutic use (20) 20
cytisine (19) 19
environmental sciences (19) 19
nicotine (19) 19
pharmacology & pharmacy (19) 19
azocines (18) 18
adult (17) 17
dose-response relationship, drug (17) 17
explosives (17) 17
nicotine - antagonists & inhibitors (17) 17
neurosciences (16) 16
quinolizines (16) 16
azocines - adverse effects (15) 15
azocines - toxicity (15) 15
quinolizines - pharmacology (15) 15
smoking cessation (15) 15
toxicology (15) 15
hmx (14) 14
rdx (14) 14
mice (13) 13
receptors, nicotinic - metabolism (13) 13
azocines - administration & dosage (12) 12
biodegradation (12) 12
nicotinic agonists - pharmacology (12) 12
nicotinic agonists - therapeutic use (12) 12
research (12) 12
smoking (12) 12
sustained-release bupropion (12) 12
2,4,6-trinitrotoluene (11) 11
azocines - metabolism (11) 11
benzazepines - therapeutic use (11) 11
nicotine - pharmacology (11) 11
placebo-controlled trial (11) 11
smoking-cessation (11) 11
alkaloids - adverse effects (10) 10
azocines - chemistry (10) 10
medicine, general & internal (10) 10
middle aged (10) 10
quinoxalines - therapeutic use (10) 10
azocines - pharmacokinetics (9) 9
double-blind (9) 9
nicotine - adverse effects (9) 9
psychiatry (9) 9
smoking - drug therapy (9) 9
alkaloids - administration & dosage (8) 8
analysis (8) 8
bupropion - therapeutic use (8) 8
clinical trials as topic (8) 8
explosive agents - toxicity (8) 8
hexahydro-1,3,5-trinitro-1,3,5-triazine (8) 8
octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (8) 8
pregnancy (8) 8
quinolizines - adverse effects (8) 8
randomized controlled trials as topic (8) 8
rats, wistar (8) 8
time factors (8) 8
alkaloids - metabolism (7) 7
biodegradation, environmental (7) 7
biotransformation (7) 7
efficacy (7) 7
fate (7) 7
quinolizines - administration & dosage (7) 7
randomized controlled-trial (7) 7
rats, sprague-dawley (7) 7
receptor partial agonist (7) 7
receptors, nicotinic - drug effects (7) 7
rodents (7) 7
soil pollutants - toxicity (7) 7
treatment outcome (7) 7
triazines - metabolism (7) 7
triazines - toxicity (7) 7
acetylcholine-receptors (6) 6
aged (6) 6
alkaloids (6) 6
alkaloids [therapeutic use] (6) 6
alpha-4-beta-2 (6) 6
azocines [therapeutic use] (6) 6
cessation (6) 6
heterocyclic compounds, 1-ring - toxicity (6) 6
metabolism (6) 6
nicotinic agonists - adverse effects (6) 6
quinolizines [therapeutic use] (6) 6
soil (6) 6
substance withdrawal syndrome - prevention & control (6) 6
tobacco use disorder - drug therapy (6) 6
toxicity (6) 6
alzheimers-disease (5) 5
anaerobiosis (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Nicotine receptor partial agonists for smoking cessation
by Cahill, Kate and Lindson-Hawley, Nicola and Thomas, Kyla H and Fanshawe, Thomas R and Lancaster, Tim
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2016, Volume 2016, Issue 5, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Smoking [drug therapy] | Varenicline | Humans | RANDOMIZED CONTROLLED-TRIAL | Quinolizines [therapeutic use] | PSYCHIATRIC ADVERSE EVENTS | TOBACCO-DEPENDENCE TREATMENT | Quinoxalines [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Bupropion [therapeutic use] | Nicotine [adverse effects; antagonists & inhibitors] | REPLACEMENT THERAPY | SUSTAINED-RELEASE BUPROPION | Smoking Cessation [methods] | Counseling [methods] | VARENICLINE TREATMENT | METHADONE-MAINTAINED SMOKERS | Randomized Controlled Trials as Topic | Azepines [therapeutic use] | DOUBLE-BLIND PLACEBO | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | Azocines [therapeutic use] | LONG-TERM SAFETY | Benzazepines [therapeutic use] | PLACEBO-CONTROLLED TRIAL | Substance Withdrawal Syndrome [prevention & control] | Heterocyclic Compounds with 4 or More Rings [therapeutic use] | Quinolizines - therapeutic use | Azepines - adverse effects | Azocines - therapeutic use | Azocines - adverse effects | Substance Withdrawal Syndrome - prevention & control | Alkaloids - adverse effects | Benzazepines - adverse effects | Smoking - drug therapy | Heterocyclic Compounds, 4 or More Rings - adverse effects | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Quinolizines - adverse effects | Varenicline - therapeutic use | Bupropion - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Nicotine receptor partial agonists for smoking cessation
by Cahill, Kate and Stead, Lindsay F and Lancaster, Tim
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 4, Issue 4, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
COST-EFFECTIVENESS | Smoking [drug therapy] | Humans | VARENICLINE TREATMENT | Quinolizines [therapeutic use] | PSYCHIATRIC ADVERSE EVENTS | Randomized Controlled Trials as Topic | TOBACCO DEPENDENCE | Quinoxalines [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | BUPROPION SR | Azocines [therapeutic use] | Bupropion [therapeutic use] | Nicotine [adverse effects; antagonists & inhibitors] | LONG-TERM SAFETY | DOUBLE-BLIND | REPLACEMENT THERAPY | CARDIOVASCULAR-DISEASE | Benzazepines [therapeutic use] | PLACEBO-CONTROLLED TRIAL | Substance Withdrawal Syndrome [prevention & control] | Smoking Cessation [methods] | Quinolizines - therapeutic use | Azocines - therapeutic use | Substance Withdrawal Syndrome - prevention & control | Varenicline | Smoking - drug therapy | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Bupropion - therapeutic use | Quinoxalines - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cytisine versus Nicotine for Smoking Cessation
by Walker, Natalie and Howe, Colin and Glover, Marewa and McRobbie, Hayden and Barnes, Joanne and Nosa, Vili and Parag, Varsha and Bassett, Bruce and Bullen, Christopher
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2353 - 2362
In this trial involving smokers who called the New Zealand national quitline, cytisine (a partial agonist of the nicotinic acetylcholine receptor) was superior... 
TRIAL | MEDICINE, GENERAL & INTERNAL | NEW-ZEALAND | FAGERSTROM TEST | EFFICACY | REPLACEMENT THERAPY | VARENICLINE | Quinolizines - therapeutic use | Nicotine - therapeutic use | Azocines - therapeutic use | Azocines - adverse effects | Nausea - chemically induced | Alkaloids - adverse effects | Humans | Middle Aged | Male | Tobacco Use Disorder - drug therapy | Treatment Outcome | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Nicotine - adverse effects | Tobacco Use Cessation Products | Adult | Alkaloids - therapeutic use | Female | Quinolizines - adverse effects | Drugs | Smoking cessation programs | Adverse and side effects | Research | Smoking cessation products | Health aspects | Risk factors | Studies | Smoking cessation | Sleep disorders | Medical research | Drug addiction | Sleep | Vomiting | Clinical trials | Blood pressure | Nausea | Chemical compounds | Nicotine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? a systematic review and economic evaluation
by Leaviss, Joanna and Sullivan, William and Ren, Shijie and Everson-Hock, Emma and Stevenson, Matt and Stevens, John W and Strong, Mark and Cantrell, Anna
Health Technology Assessment, ISSN 1366-5278, 2014, Volume 18, Issue 33, pp. 1 - 119
Background: Tobacco smoking is one of the leading causes of deaths worldwide. Nearly one-fifth of adults in the UK regularly smoke cigarettes. The ill-health... 
STOP SMOKING | NICOTINE PATCH | HELPING SMOKERS | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | RANDOMIZED CONTROLLED-TRIAL | QUALITY-OF-LIFE | RECEPTOR PARTIAL AGONIST | SUSTAINED-RELEASE BUPROPION | ADVERSE EVENTS | Quinolizines - therapeutic use | Quinoxalines - adverse effects | Azocines - therapeutic use | Benzazepines - economics | State Medicine | Azocines - adverse effects | Benzazepines - adverse effects | Humans | Middle Aged | Varenicline | Nicotinic Agonists - economics | Quinolizines - economics | Adult | Quinolizines - adverse effects | Alkaloids - economics | Quinoxalines - therapeutic use | Quality-Adjusted Life Years | Alkaloids - adverse effects | Smoking Cessation - economics | Smoking - economics | United Kingdom | Quinoxalines - economics | Nicotinic Agonists - therapeutic use | Smoking Cessation - methods | Nicotinic Agonists - adverse effects | Randomized Controlled Trials as Topic | Benzazepines - therapeutic use | Cost-Benefit Analysis | Alkaloids - therapeutic use | Aged | Azocines - economics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Nicotine receptor partial agonists for smoking cessation
by Cahill, Kate and Stead, Lindsay F and Lancaster, Tim
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2008, Issue 3, pp. CD006103 - CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Quinoxalines [therapeutic use] | Nicotinic agonists [therapeutic use] | Alkaloids [therapeutic use] | Azocines [therapeutic use] | Benzazepines [therapeutic use] | Nicotine [antagonists & inhibitors] | Quinolizines [therapeutic use] | MEDICINE, GENERAL & INTERNAL | PLACEBO | CONTROLLED TRIAL | THERAPY | CYTISINE | EFFICACY | TOLERABILITY | LONG-TERM SAFETY | SUSTAINED-RELEASE BUPROPION | VARENICLINE | ALPHA-4-BETA-2 | Quinolizines - therapeutic use | Quinoxalines - adverse effects | Azocines - therapeutic use | Benzazepines - adverse effects | Humans | Varenicline | Smoking - drug therapy | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Nicotinic Agonists - adverse effects | Randomized Controlled Trials as Topic | Benzazepines - therapeutic use | Alkaloids - therapeutic use | Bupropion - therapeutic use | Quinoxalines - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Nicotine receptor partial agonists for smoking cessation
by Cahill, K and Stead, LF and Lancaster, T
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ISSN 1469-493X, 2011, Issue 2, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Smoking [drug therapy] | EFFICACY | Benzazepines [adverse effects; therapeutic use] | Humans | VARENICLINE TREATMENT | Quinoxalines [adverse effects; therapeutic use] | Nicotine [antagonists & inhibitors] | Quinolizines [therapeutic use] | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | Azocines [therapeutic use] | Bupropion [therapeutic use] | SMOKERS | LONG-TERM SAFETY | CLINICAL-TRIALS | COST-UTILITY | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | SUSTAINED-RELEASE BUPROPION | Smoking Cessation [methods] | ALPHA-4-BETA-2 | Quinolizines - therapeutic use | Azocines - therapeutic use | Substance Withdrawal Syndrome - prevention & control | Varenicline | Smoking - drug therapy | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Benzazepines - therapeutic use | Alkaloids - therapeutic use | Bupropion - therapeutic use | Quinoxalines - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study
by Hurwitz, Herbert I and Smith, David C and Pitot, Henry C and Brill, Jeffrey M and Chugh, Rashmi and Rouits, Elisabeth and Rubin, Joseph and Strickler, John and Vuagniaux, Gregoire and Sorensen, J. Mel and Zanna, Claudio
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2015, Volume 75, Issue 4, pp. 851 - 859
To assess safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of DEBIO1143, an antagonist of inhibitor apoptosis... 
Resistance | IAP | DEBIO1143 | Apoptosis | AT-406 | Cancer | CRITERIA | APOPTOSIS PROTEINS IAPS | MULTIPLE INHIBITOR | ANTAGONIST SM-406/AT-406 | ONCOLOGY | TARGETS | PHARMACOLOGY & PHARMACY | ACTIVE ANTAGONIST | Azocines - therapeutic use | Neoplasms - etiology | Azocines - adverse effects | Benzhydryl Compounds - administration & dosage | Apoptosis - drug effects | Humans | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Benzhydryl Compounds - adverse effects | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzhydryl Compounds - therapeutic use | Benzhydryl Compounds - pharmacokinetics | Azocines - pharmacokinetics | Administration, Oral | Treatment Outcome | Chemokine CCL2 - blood | Neoplasms - drug therapy | Maximum Tolerated Dose | Azocines - administration & dosage | Neoplasms - pathology | Inhibitor of Apoptosis Proteins - blood | Proteins | Care and treatment | Safety and security measures | Analysis | Oncology, Experimental | Development and progression | Nausea | Research | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Nicotine receptor partial agonists for smoking cessation
by Cahill, K and Stead, LF and Lancaster, T
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ISSN 1469-493X, 2010, Issue 12, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
PLACEBO | Smoking [drug therapy] | CONTROLLED TRIAL | EFFICACY | Benzazepines [adverse effects; therapeutic use] | Humans | VARENICLINE TREATMENT | Quinoxalines [adverse effects; therapeutic use] | Nicotine [antagonists & inhibitors] | Quinolizines [therapeutic use] | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | Azocines [therapeutic use] | Bupropion [therapeutic use] | SMOKERS | LONG-TERM SAFETY | CLINICAL-TRIALS | COST-UTILITY | DOUBLE-BLIND | SUSTAINED-RELEASE BUPROPION | Smoking Cessation [methods] | Quinolizines - therapeutic use | Quinoxalines - adverse effects | Azocines - therapeutic use | Substance Withdrawal Syndrome - prevention & control | Benzazepines - adverse effects | Varenicline | Smoking - drug therapy | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Benzazepines - therapeutic use | Alkaloids - therapeutic use | Bupropion - therapeutic use | Quinoxalines - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis
by Hajek, Peter and McRobbie, Hayden and Myers, Katie
Thorax, ISSN 0040-6376, 11/2013, Volume 68, Issue 11, pp. 1037 - 1042
Background A recent rigorous study has shown that cytisine, a low-cost drug, is effective for smoking cessation. A number of earlier studies exist, mostly from... 
SMOKING-CESSATION | PLACEBO-CONTROLLED TRIAL | Not Applicable | VARENICLINE | RESPIRATORY SYSTEM | Smoking - adverse effects | Public Health | Alkaloids - pharmacology | Humans | Treatment Outcome | Azocines - pharmacology | Quinolizines - pharmacology | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Smoking Prevention | Alkaloids | Smoking cessation programs | Influence | Usage | Research | Meta-analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Cytisine for smoking cessation: A research agenda
by Etter, Jean-François and Lukas, Ronald J and Benowitz, Neal L and West, Robert and Dresler, Carolyn M
Drug and Alcohol Dependence, ISSN 0376-8716, 2007, Volume 92, Issue 1, pp. 3 - 8
Abstract Cytisine has a molecular structure somewhat similar to that of nicotine and varenicline. The concept for the new smoking cessation drug varenicline... 
Psychiatry | Cytisine | Smoking cessation | Tobacco use disorder | PLACEBO | tobacco use disorder | EFFICACY | PSYCHIATRY | ALPHA-7 | SUBSTANCE ABUSE | RECEPTOR PARTIAL AGONIST | NICOTINIC ACETYLCHOLINE-RECEPTORS | cytisine | THERAPY | smoking cessation | DISCRIMINATIVE STIMULUS PROPERTIES | SUSTAINED-RELEASE BUPROPION | VARENICLINE | DERIVATIVES | Quinolizines - pharmacokinetics | Quinolizines - therapeutic use | Quinolizines - toxicity | Alkaloids - toxicity | Azocines - pharmacokinetics | Azocines - therapeutic use | Azocines - adverse effects | Alkaloids - pharmacokinetics | Drug Overdose | Alkaloids - adverse effects | Humans | Clinical Trials as Topic | Azocines - toxicity | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Animals | Substance-Related Disorders - psychology | Alkaloids - therapeutic use | Quinolizines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A ten fold reduction of nicotine yield in tobacco smoke does not spare the central cholinergic system in adolescent mice
by Abreu-Villaça, Yael and Correa-Santos, Monique and Dutra-Tavares, Ana C and Paes-Branco, Danielle and Nunes-Freitas, Andre and Manhães, Alex C and Filgueiras, Cláudio C and Ribeiro-Carvalho, Anderson
International Journal of Developmental Neuroscience, ISSN 0736-5748, 08/2016, Volume 52, pp. 93 - 103
The tobacco industry has gradually decreased nicotine content in cigarette smoke but the impact of this reduction on health is still controversial. Since the... 
Cigarette | Development | Denicotinized | Drugs of abuse | nAChR | Smoking | SEROTONERGIC SYSTEMS | DEVELOPMENTAL BIOLOGY | RAT-BRAIN REGIONS | NEUROSCIENCES | ACETYLCHOLINE-RECEPTORS | COMBINED EXPOSURE | PERINATAL EXPOSURE | GENE-EXPRESSION | NEURONS | BINDING-SITES | UP-REGULATION | WITHDRAWAL | Quinolizines - pharmacokinetics | Central Nervous System - metabolism | Acetyl Coenzyme A - pharmacokinetics | Age Factors | Alkaloids - pharmacokinetics | Male | Choline O-Acetyltransferase - metabolism | Nicotine - pharmacology | Dose-Response Relationship, Drug | Carbon Isotopes - pharmacokinetics | Protein Binding - drug effects | Female | Nicotinic Agonists - pharmacology | Animals, Newborn | Azocines - pharmacokinetics | Receptors, Nicotinic - metabolism | Smoke - adverse effects | Up-Regulation - drug effects | Animals | Sex Factors | Central Nervous System - drug effects | Mice | Tobacco - adverse effects | Acetylcholinesterase - metabolism | Tritium - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The Past, Present, and Future of Nicotine Addiction Therapy
by Prochaska, Judith J and Benowitz, Neal L
Annual Review of Medicine, ISSN 0066-4219, 1/2016, Volume 67, Issue 1, pp. 467 - 486
The tobacco addiction treatment field is progressing through innovations in medication development, a focus on precision medicine, and application of new... 
cigarette | tobacco | quitline | smoking | cessation | vape | Cigarette | Vape | Quitline | Tobacco | Cessation | Smoking | MEDICINE, RESEARCH & EXPERIMENTAL | HELPING SMOKERS QUIT | SMOKING-CESSATION | EFFICACY | RANDOMIZED CONTROLLED-TRIAL | ELECTRONIC CIGARETTES | REPLACEMENT THERAPY | DOUBLE-BLIND | TOBACCO USE | SUSTAINED-RELEASE BUPROPION | VARENICLINE | Quinolizines - therapeutic use | Nicotine - administration & dosage | Azocines - therapeutic use | Social Media | Humans | Dopamine Uptake Inhibitors - therapeutic use | Nicotinic Agonists - therapeutic use | Directive Counseling | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Nicotine - adverse effects | Nicotine - metabolism | Tobacco Use Disorder - etiology | Tobacco Use Cessation Products | Text Messaging | Alkaloids - therapeutic use | Varenicline - therapeutic use | Drug Therapy, Combination | Health Policy | Bupropion - therapeutic use | Tobacco Use Disorder - therapy | Smoking cessation programs | Forecasts and trends | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights